


AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

1-20. (Canceled)

21. (Currently amended) A compound of formula (I)



(I)


wherein

R is ~~a nitrogen-containing one or two ring moiety consisting of one or two aromatic rings~~pyridyl, optionally mono- or disubstituted independently by C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, trihalogenomethyl, methylthio, nitro, cyano, C₂₋₅ alkoxy carbonyl or carboxamido; ~~p-tolylsulfonyl~~;

R_{1a}-CH₂ where R_{1a} is ~~hydrogen, C₁₋₄ alkyl, phenyl, benzyl, phenylethyl, phenylethenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, cinnolyl, phthalazinyl, quinazolinyl, quinoxalyl, thienyl, furyl or p-tolylsulfonyl~~ optionally independently substituted with one or more C₁₋₄ alkyl, C₁₋₄ alkoxy, alkylenedioxy, halogen, trihalogenomethyl, nitro or cyano; or


R_{1b}-CO, where R_{1b} is ~~C₁₋₄ alkyl, phenyl, benzyl, phenylethyl, phenylethenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, cinnolyl, phthalazinyl, quinazolinyl or quinoxalyl~~ optionally independently substituted with one or more C₁₋₄ alkyl, C₁₋₄ alkoxy, alkylenedioxy, halogen, trihalogenomethyl, nitro or cyano; or R_{1b} is ~~mono or disubstituted amino, or a saturated N-containing heterocyclic group~~piperidino;

B is a group of formula (1), (2), (3), or (4)



and

Z is a group of formula (A), (B), (C), (D), (E), or (F);



or a salt, isomer, tautomer, or hydrate ~~or solvate~~ thereof.

22. (Canceled).

23. (Currently amended) ~~A~~The compounds according to ~~C~~claim 2221 wherein

R is ~~pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pirazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, quinoliny, isoquinoliny, cinnoliny, phthalazinyl, quinazolinyl, quinoxalinyl, benzimidazolyl, indazolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl or benzisoxazolyl~~ optionally independently mono- or disubstituted with C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, trihalogenomethyl, methylthio, nitro, or cyano;
~~p-tolylsulfonyl;~~

R_{1a}-CH₂, where R_{1a} is ~~hydrogen, C1-4 alkyl, phenyl, benzyl, phenylethyl, phenylethenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, cinnoliny, phthalazinyl, quinazolinyl, quinoxalinyl, thienyl, furyl or p-tolylsulfonyl~~ optionally independently substituted with one or more C₁₋₄ alkyl, C₁₋₄ alkoxy, alkylenedioxy, halogen, trihalogenomethyl, nitro or cyano; or

R_{1b}-CO where R_{1b} is ~~C1-4 alkyl, phenyl, benzyl, phenylethyl, phenylethenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, cinnoliny, phthalazinyl, quinazolinyl or quinoxalinyl~~ optionally independently substituted with one or more C₁₋₄ alkyl, C₁₋₄ alkoxy, alkylenedioxy, halogen, trihalogenomethyl, nitro or cyano; or R_{1b} is ~~mono- or disubstituted amino, or a saturated N-containing heterocyclic group containing pyrrolidino, piperidino, piperazine or morpholine;~~

or a salt, isomer, tautomer, or hydrate thereof.

24. (Currently amended) ~~A~~The compound according to ~~C~~claim 2221 wherein

R is ~~pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, or benzisoxazolyl~~ optionally independently mono- or disubstituted with C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, nitro, cyano, C₂₋₅ alkoxycarbonyl or carboxamido;
~~p-tolylsulfonyl;~~

~~R_{1a}-CH₂ wherein R_{1a} is benzyl or phenylethenyl optionally independently substituted with one or more C1-4 alkyl or alkylenedioxy; or~~

~~R_{1b}CO where R_{1b} is phenyl, benzyl, phenylethyl, or phenylethenyl optionally substituted with alkylenedioxy, or R_{1b} is piperidino; and~~

Z is a group of formula (A) or formula (B);

or a salt, isomer, tautomer, or hydrate thereof.

25. (Currently amended) ~~A~~The compound according to ~~C~~claim 24 wherein

R is ~~pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, or benzisoxazolyl~~ optionally independently mono- or disubstituted with C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, nitro, or cyano;
~~p-tolylsulfonyl;~~

~~R_{1a}—CH₂ wherein R_{1a} is benzyl or phenylethenyl optionally independently substituted with one or more C1-4 alkyl or alkylendioxy; or~~

~~R_{1b}CO where R_{1b} is phenyl, benzyl, phenylethyl, or phenylethenyl optionally independently substituted with alkylendioxy; or R_{1b} is piperidino;~~

or a salt, isomer, tautomer, or hydrate thereof.

26. (Currently amended) ~~A~~The compound according to ~~C~~claim 25 wherein R is ~~pyrimidinyl, pyridyl, or pyrazinyl~~ substituted with nitro or cyano, and B is a group of formula (1) or (2); or a salt, isomer, tautomer, or hydrate thereof.

27. (Currently amended) A compound selected from the group consisting of:

~~(4R)-3-(2-[[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]-exo-amino}acetyl)thiazolidine-4-carbonitrile;~~
~~(4R)-3-(2-[[8-(5-Cyanopyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]-exo-amino}acetyl)thiazolidine-4-~~
~~carbonitrile;~~

~~(4R)-3-(2-[[8-(5-Cyanopyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]-endo-amino}acetyl)thiazolidine-4-~~
~~carbonitrile;~~

~~(4R)-3-(2-[[8-(2-Pyrazinyl)-8-azabicyclo[3.2.1]octan-3-yl]-exo-amino}acetyl)thiazolidine-4-carbonitrile;~~
and

~~(2S)-1-(2-[[8-(5-Nitropyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]-exo-amino}acetyl)pyrrolidine-2-~~
~~carbonitrile;~~

~~or a salt, or hydrate, or solvate thereof.~~

28. (Currently amended) A pharmaceutical composition comprising a compound according to ~~C~~claim 21 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

29. (Canceled)

30. (Currently amended) A pharmaceutical composition comprising a compound according to ~~C~~claim 23 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.


31. (Currently amended) A pharmaceutical composition comprising a compound according to ~~C~~claim 24 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

32. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 25 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

33. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 26 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.


34. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 27 or a salt, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

35. (Currently amended) A process for ~~the preparation of~~preparing the compounds of a compound according to Claim 21 which comprises~~comprising~~ reacting a compound of formula (II)



(II)

with a compound of formula (III)



(III)

wherein in the above formulas R, B, and Z are as defined in Claim 21.

36-43. (Canceled)


44. (Currently amended) A compound of ~~the~~ formula



wherein

R is ~~a nitrogen-containing one or two ring moiety consisting of one or two aromatic rings~~pyridyl, optionally mono- or disubstituted independently by C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, trihalogenomethyl, methylthio, nitro, cyano, C₂₋₅ alkoxy carbonyl or carboxamido; p-tolylsulfonyl;

B is a group of formula (1), (2), (3), or (4)



Y is hydrogen or tert-butoxycarbonyl;
or a salt thereof.

45. (Canceled)